BioXcel Financial Statements (BTAI)
|
|
|
|
Report date
|
|
|
12.03.2021 |
11.03.2022 |
16.03.2023 |
01.05.2023 |
22.03.2024 |
|
14.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.375 |
0.375 |
1.38 |
|
2.28 |
|
Operating Income, bln rub |
|
|
-82.3 |
-106.9 |
-159.6 |
-159.6 |
-171.8 |
|
-75.0 |
|
EBITDA, bln rub |
? |
|
-82.0 |
-107.0 |
-157.5 |
-157.4 |
-165.4 |
|
-56.2 |
|
Net profit, bln rub |
? |
|
-82.0 |
-106.6 |
-171.8 |
-171.8 |
-179.1 |
|
-71.0 |
|
|
OCF, bln rub |
? |
|
-66.4 |
-82.2 |
-135.3 |
-135.3 |
-155.0 |
|
-84.1 |
|
CAPEX, bln rub |
? |
|
0.316 |
0.445 |
0.139 |
0.139 |
0.020 |
|
0.000 |
|
FCF, bln rub |
? |
|
-66.7 |
-82.6 |
-135.5 |
-135.5 |
-155.0 |
|
-84.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
82.3 |
106.9 |
160.0 |
160.0 |
171.9 |
|
75.0 |
|
Cost of production, bln rub |
|
|
0.188 |
0.297 |
0.020 |
0.020 |
1.26 |
|
2.18 |
|
R&D, bln rub |
|
|
58.0 |
52.7 |
91.2 |
91.2 |
84.3 |
|
34.0 |
|
Interest expenses, bln rub |
|
|
0.027 |
0.040 |
8.21 |
8.21 |
13.3 |
|
14.5 |
|
|
Assets, bln rub |
|
|
219.9 |
239.4 |
205.9 |
205.9 |
73.7 |
|
48.9 |
|
Net Assets, bln rub |
? |
|
206.7 |
221.7 |
76.8 |
76.8 |
-56.5 |
|
-85.6 |
|
Debt, bln rub |
|
|
1.64 |
1.40 |
94.2 |
94.2 |
101.4 |
|
104.6 |
|
Cash, bln rub |
|
|
213.1 |
233.0 |
193.7 |
193.7 |
65.2 |
|
40.4 |
|
Net debt, bln rub |
|
|
-211.5 |
-231.6 |
-99.6 |
-99.6 |
36.2 |
|
64.2 |
|
|
Ordinary share price, rub |
|
|
46.2 |
20.3 |
21.5 |
21.5 |
2.95 |
|
4.00 |
|
Number of ordinary shares, mln |
|
|
21.7 |
26.4 |
28.0 |
28.0 |
29.1 |
|
42.4 |
|
|
Market cap, bln rub |
|
|
1 002 |
536 |
602 |
602 |
86 |
|
170 |
|
EV, bln rub |
? |
|
790 |
305 |
502 |
502 |
122 |
|
234 |
|
Book value, bln rub |
|
|
207 |
222 |
77 |
77 |
-57 |
|
-86 |
|
|
EPS, rub |
? |
|
-3.78 |
-4.04 |
-6.13 |
-6.13 |
-6.15 |
|
-1.67 |
|
FCF/share, rub |
|
|
-3.07 |
-3.13 |
-4.84 |
-4.84 |
-5.32 |
|
-1.98 |
|
BV/share, rub |
|
|
9.53 |
8.41 |
2.74 |
2.74 |
-1.94 |
|
-2.02 |
|
|
EBITDA margin, % |
? |
|
|
|
-42 012% |
-41 969% |
-11 987% |
|
-2 467% |
|
Net margin, % |
? |
|
|
|
-45 826% |
-45 826% |
-12 975% |
|
-3 119% |
|
FCF yield, % |
? |
|
-6.65% |
-15.4% |
-22.5% |
-22.5% |
-180.4% |
|
-49.6% |
|
ROE, % |
? |
|
-39.7% |
-48.1% |
-223.8% |
-223.8% |
316.9% |
|
82.9% |
|
ROA, % |
? |
|
-37.3% |
-44.5% |
-83.5% |
-83.5% |
-242.9% |
|
-145.2% |
|
|
P/E |
? |
|
-12.2 |
-5.03 |
-3.50 |
-3.50 |
-0.48 |
|
-2.39 |
|
P/FCF |
|
|
-15.0 |
-6.49 |
-4.44 |
-4.44 |
-0.55 |
|
-2.02 |
|
P/S |
? |
|
|
|
1 605 |
1 605 |
62.3 |
|
74.5 |
|
P/BV |
? |
|
4.85 |
2.42 |
7.84 |
7.84 |
-1.52 |
|
-1.98 |
|
EV/EBITDA |
? |
|
-9.64 |
-2.85 |
-3.19 |
-3.19 |
-0.74 |
|
-4.16 |
|
Debt/EBITDA |
|
|
2.58 |
2.16 |
0.63 |
0.63 |
-0.22 |
|
-1.14 |
|
|
R&D/CAPEX, % |
|
|
18 353% |
11 844% |
65 640% |
65 640% |
421 630% |
|
|
|
|
CAPEX/Revenue, % |
|
|
|
|
37.1% |
37.1% |
1.45% |
|
0 |
|
| BioXcel shareholders |
